Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination. Issue 3 (22nd October 2013)

• Record Type: Journal Article
• Authors: Shimoda, Seiya; Iwashita, Shinsuke; Sekigami, Taiji; Furukawa, Noboru; Matsuo, Yasuto; Ichimori, Shinji; Goto, Rieko; Maeda, Takako; Watanabe, Eiichiro; Kondo, Tatsuya; Matsumura, Takeshi; Motoshima, Hiroyuki; Nishida, Kenro; Araki, Eiichi
• Is Part Of: Journal of diabetes investigation. Volume 5:Issue 3(2014:Jun.)
• Page Start: 320
• Page End: 326
• Publication Date: 2013-10-22
• Subjects: Diabetes -- Periodicals; Diabetes -- Research -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1111/jdi.12151
• Languages: English
• ISSNs: 2040-1116

Abstract

<abstract abstract-type="main" id="jdi12151-abs-0001"> <title>Abstract</title> <sec id="jdi12151-sec-0001" sec-type="section"> <title>Aims/Introduction</title> <p>The goal of the study was to examine the effects of sitagliptin dose‐up or glimepiride dose‐up in Japanese patients with type 2 diabetes who were controlled inadequately by sitagliptin and glimepiride in combination.</p> </sec> <sec id="jdi12151-sec-0002" sec-type="section"> <title>Materials and Methods</title> <p>A multicenter, prospective, randomized, open‐label study was carried out in 50 patients with type 2 diabetes treated with sitagliptin and low‐dose glimepiride. The patients were randomly assigned to receive the addition of 50 mg/day sitagliptin or 0.5 mg/day glimepiride. The primary end‐point was the percentage change in glycated hemoglobin (HbA1c).</p> </sec> <sec id="jdi12151-sec-0003" sec-type="section"> <title>Results</title> <p>During a follow‐up period, the difference in the percentage changes in HbA1c between the two groups was not significant (<italic>P</italic> = 0.13). However, HbA1c was significantly decreased by glimepiride dose‐up (<italic>P</italic> < 0.01 vs baseline), but not by sitagliptin dose‐up (<italic>P</italic> = 0.74). Univariate linear regression analyses showed that the percentage change in HbA1c was significantly associated with the serum level of arachidonic acid (AA) in both groups.</p> </sec> <sec id="jdi12151-sec-0004" sec-type="section"> <title>Conclusions</title> <p>There was no significant difference in the HbA1c‐lowering effects between the two groups. However, a significant HbA1c‐lowering effect from baseline of glimepiride dose‐up was found, and the AA level showed a negative correlation with the decrease in HbA1c in the sitagliptin dose‐up group, but a positive correlation in the glimepiride dose‐up group. These findings suggest that the AA level is associated with HbA1c reduction in response to dose‐up with these drugs in patients with type 2 diabetes in a combination therapy with sitagliptin and glimepiride. This trial was registered with UMIN (no. 000009544).</p> </sec> </abstract>